Literature DB >> 10546935

Successful closure of traumatic macular holes.

D R Chow1, G A Williams, M T Trese, R R Margherio, A J Ruby, P J Ferrone.   

Abstract

PURPOSE: To establish the efficacy of vitreoretinal surgery without the use of transforming growth factor-beta or autologous platelet concentrate in the repair of traumatic macular holes.
METHODS: This retrospective review consisted of 16 eyes from 16 consecutive patients treated by five vitreoretinal surgeons at a single institution between 1993 and 1997. Intervention included pars plana vitrectomy with creation of posterior vitreous detachment, placement of 14% to 16% C3F8 gas, and postoperative face-down positioning. Ten eyes received intraoperative autologous plasmin to facilitate formation of posterior vitreous detachment. Main outcome measures were anatomic closure rate and visual outcome.
RESULTS: Anatomic closure of the macular holes was achieved in 15 (94%) of 16 eyes, with an average follow-up of 7 months. Six (38%) eyes achieved visual acuity of 20/40 or better. Visual acuity improved by 2 or more lines in 11 (69%) of 16 eyes. The average preoperative logMAR-converted visual acuity of 20/175 improved to 20/60 postoperatively.
CONCLUSION: Traumatic macular holes can be closed successfully with substantial visual recovery without the use of transforming growth factor-beta or platelet concentrate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10546935     DOI: 10.1097/00006982-199909000-00006

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  14 in total

1.  [Spontaneous closure of traumatic macular holes. Two cases].

Authors:  R Khoramnia; C W Mohrenfels; J P Salgado; I M Lanzl; C P Lohmann; C Mayer
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

2.  Safety profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit.

Authors:  M Hermel; M Mahgoub; T Youssef; M I Azrak; H Raza; C Alldredge; M Trese; G A Williams; M Hartzer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-12-20       Impact factor: 3.117

3.  A disposable system for rapid purification of autologous plasmin as an adjunct to vitrectomy - performance and safety profile.

Authors:  Martin Hermel; Wendelin Dailey; Michael Trese; Michael K Hartzer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-03       Impact factor: 3.117

4.  Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study.

Authors:  Martin Hermel; Norbert F Schrage
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-10       Impact factor: 3.117

Review 5.  [Blunt ocular trauma. Part II. Blunt posterior segment trauma].

Authors:  A Viestenz; M Küchle
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059

6.  Improving morphological outcome in lamellar macular hole surgery by using highly concentrated autologous platelet-rich plasma.

Authors:  Felix Hagenau; Nikolaus Luft; Matthias Nobl; Denise Vogt; Julian E Klaas; Benedikt Schworm; Jakob Siedlecki; Thomas C Kreutzer; Siegfried G Priglinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-12-06       Impact factor: 3.117

Review 7.  Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease.

Authors:  J Sebag
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08       Impact factor: 3.117

8.  Long term result of silicone oil versus gas tamponade in the treatment of traumatic macular holes.

Authors:  Hammouda H Ghoraba; Amin F Ellakwa; Ali A Ghali
Journal:  Clin Ophthalmol       Date:  2012-01-09

9.  Management of pediatric traumatic macular holes - case report.

Authors:  S Azevedo; N Ferreira; A Meireles
Journal:  Case Rep Ophthalmol       Date:  2013-06-06

10.  Posttraumatic horseshoe-shaped macular tear.

Authors:  Neha Goel; Ravi Sharma; Madhullika Mandal; Reena M Choudhry
Journal:  Indian J Ophthalmol       Date:  2014-11       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.